---
title: "practice guidelines perioperative management antithromuotic medi"
year: 2023
month: 08
journal: "American Family Physician"
volume: "108"
issue: "08"
pages: ""
doi: ""
pmid: ""
source: "PDF Extraction"
pdf_available: true
original_pdf: "2023-08-practice-guidelines-perioperative-management-antithrombotic-medi.pdf"
extracted_date: "2025-08-10"
keywords: []
evidence_level: ""
clinical_significance: ""
---

# practice guidelines perioperative management antithromuotic medi

                                                Practice Guidelines
         Perioperative Management of
 Antithrombotic Medications:​Guidelines From
   the American College of Chest Physicians
                                                                                  high-bleeding risk, most medications are stopped
  Key Points for Practice
                                                                                  before surgery and later restarted. Patient or sur-
  • Perioperative antithrombotic management depends on
     balancing bleeding risk with risk for thrombosis;​for sur-
                                                                                  gical factors may increase bleeding risk.
     geries with minimal bleeding risk, continue antithrombotic                     Knowing the risk for thrombosis is import-
     treatment.                                                                   ant if medications are held, especially when
  • Because of their rapid onset and degradation, most direct                    antithrombotic medications are held for longer
     oral anticoagulants can be stopped one to two days before a                  periods of time. Because direct oral anticoagu-
     procedure and restarted one to two days after the procedure
     in patients without significant chronic kidney disease.
                                                                                  lants are held for a short period of time, bridging
                                                                                  with heparin is generally not recommended. The
  • Bridging with heparin for patients taking warfarin is reserved
     for those at high risk of thromboembolism in most cases.                     American College of Chest Physicians suggests
  • Aspirin can be continued through most surgeries.                             heparin bridging for high thrombotic risk con-
                                                  From the AFP Editors
                                                                                  ditions if the patient is taking a vitamin K antag-
                                                                                  onist (Table 2).

             Up to 20% of patients taking antithrombotic
             medications will need an invasive procedure. The                          G-TRUST GUIDELINE SCORECARD
             American College of Chest Physicians published
             updated guidelines on perioperative management                                Score         Criteria
             of antithrombotic medications for elective proce-
                                                                                            Yes          Focus on patient-oriented outcomes
             dures based on a systematic review of primarily
             low-quality evidence.                                                          Yes          Clear and actionable recommendations

             Balance of Risks                                                               Yes          Relevant patient populations and conditions

             The risk of bleeding following a procedure and the                             Yes          Based on systematic review
             risk of thromboembolism from the initial need
                                                                                            Yes          Evidence graded by quality
             for antithrombotic treatment are the two factors
             used to determine whether and how long to hold                                              Separate evidence review or analyst in guide-
                                                                                            Yes
             medications. Table 1 stratifies common surgeries                                            line team
             by bleeding risk. For procedures with minimal                                               Chair and majority free of conflicts of interest
             bleeding risk, the antithrombotic medication can                                            (both chairs report significant conflicts of
                                                                                         Cannot
             generally be continued. For low- to moderate- or                             tell
                                                                                                         interest but recusal from the pharmaceutical
                                                                                                         companies as of 2021;​both recused from
                                                                                                         voting)

                Coverage of guidelines from other organizations                                          Development group includes most relevant
                                                                                         Cannot
                does not imply endorsement by AFP or the AAFP.                                           specialties, patients, and payers (mix of spe-
                                                                                          tell
                This series is coordinated by Michael J. Arnold,                                         cialties, apparently no patient input)
                MD, assistant medical editor.                                                            Overall – useful
                A collection of Practice Guidelines published
                in AFP is available at https://​w ww.aafp.org/afp/                     Note:​See related editorial, Where Clinical Practice Guidelines Go
                practguide.                                                            Wrong, at https://​w ww.aafp.org/afp/gtrust.html.

                 CME This clinical content conforms to AAFP cri-                       G-TRUST = guideline trustworthiness, relevance, and utility scor-
                                                                                       ing tool.
                teria for CME. See CME Quiz on page 126.
                                                                                       Copyright © 2017 Allen F. Shaughnessy, PharmD, MMedEd, and
                Author disclosure:​ No relevant financial
                                                                                       Lisa Cosgrove, PhD. Used with permission.
                relationships.



208  American
Downloaded        Family
            from the      Physician
                     American  Family Physician website at www.aafp.org/afp.            © 2023 American AcademyVolume
                                                                                 Copyright
                                                                   www.aafp.org/afp                                     of Family108,
                                                                                                                                  Physicians.
                                                                                                                                      Number  For2theAugust
                                                                                                                                                 ◆   private, non-
                                                                                                                                                              2023
commercial use of one individual user of the website. All other rights reserved. Contact copyrights@aafp.org for copyright questions and/or permission requests.
                                                         PRACTICE GUIDELINES
TABLE 1

Bleeding Risk for Surgical Procedures
High risk                                                       Low to moderate risk                           Minimal risk

Any operation that lasts more than 45 minutes                   Abdominal hernia repair                       Cataract surgery
Cardiac surgery                                                 Abdominal hysterectomy                        Minor dental procedures
Gastrointestinal surgeries                                      Arthroscopy                                   Minor dermatologic procedures
Intracranial and spinal surgery                                 Bronchoscopy                                  Pacemaker or cardioverter-
Kidney biopsy                                                   Colonoscopy                                   defibrillator device implantation

Major orthopedic surgery                                        Coronary angiography
Major thoracic surgery                                          Gastrointestinal endoscopy
Most cancer surgeries                                           Hemorrhoidal surgery
Most urologic surgeries                                         Laparoscopic cholecystectomy
Neuraxial anesthesia and epidural injections                    Lymph node biopsy

Adapted with permission from Douketis JD, Spyropoulos AC, Murad MH, et al. Perioperative management of antithrombotic therapy:​an Ameri-
can College of Chest Physicians clinical practice guideline. Chest. 2022;​162(5):​e213.




TABLE 2

Indications for Bridging When Holding Vitamin K Antagonists
Risk level                          Mechanical heart valve              Atrial fibrillation            Venous thromboembolism

High thrombotic risk (e.g.,         Any mechanical mitral valve         CHA 2DS 2VASc score ≥ 7        Venous thromboembolism in past three
> 10% per year risk of arterial     Caged ball or tilting-disc          CHADS 2 score of 5 or 6        months
thromboembolism or > 10%            aortic valve                                                       Severe thrombophilia:​protein C, pro-
                                                                        Stroke or transient
per month risk of venous                                                                               tein S, or antithrombin deficiency or
                                    Stroke or transient ischemic        ischemic attack in past
thromboembolism)                                                                                       antiphospholipid antibody syndrome
                                    attack in past three months         three months
                                                                        Rheumatic valvular             Multiple thrombophilias
                                                                        heart disease                  Active cancer associated with high
                                                                                                       venous thromboembolism risk

CHA 2 DS 2VASc = congestive heart failure, hypertension, age 75 years or older, diabetes mellitus, prior stroke or transient ischemic attack, vascular
disease history, age 65 years or older, female sex;​CHADS 2 = congestive heart failure, hypertension, age 75 years or older, diabetes, prior stroke
or transient ischemic attack.




TABLE 3

Antithrombotic Medication Hold Time Based on Bleeding Risk for Procedures
Bleeding risk     Direct oral anticoagulant                                     Vitamin K antagonist             Antiplatelet

High              Hold for 48 hours before surgery                              Hold for five days               Hold clopidogrel for five days
                  Hold dabigatran (Pradaxa) for four days if glomer-            before surgery                   before surgery
                  ular filtration rate < 50 mL per min per 1.73 m2              Bridge with heparin if           Hold ticagrelor (Brilinta) for
                  (0.83 mL per s per m2)                                        thrombotic risk is high          three to five days before surgery
                  Consider increasing hold time for severely impaired                                            Hold prasugrel (Effient) for
                  renal function, impaired hepatic function, or if                                               seven to 10 days before surgery
                  taking medications that inhibit CYP 3A4                                                        Continuing aspirin is recom-
Low to            Hold for 24 hours before surgery                              Hold for five days               mended;​hold for seven days or
moderate                                                                        before surgery                   less if holding
                  Hold dabigatran for three days if glomerular filtra-
                  tion rate < 50 mL per min per 1.73 m2                         Bridge with heparin if
                  Consider increasing hold time for severely impaired           thrombotic risk is high
                  renal function, impaired hepatic function, or if
                  taking medications that inhibit CYP 3A4

Minimal           Continue medication                                           Continue medication              Continue medication
                                                           PRACTICE GUIDELINES


Management of Direct Oral Anticoagulant                                        one to two days after the procedure in patients without sig-
Medications                                                                    nificant chronic kidney disease. If bleeding risk is higher
For procedures with minimal bleeding risk, direct oral anti-                   than minimal (i.e., low to moderate or high) and glomer-
coagulants can be continued. Because of their rapid onset                      ular filtration rate is 50 mL per min per 1.73 m2 (0.83 mL
and degradation, most direct oral anticoagulants can be                        per s per m2) or greater, stop all direct oral anticoagulants
stopped one to two days before a procedure and restarted                       one to two days before surgery (Tables 3 and 4). When the



   TABLE 4

   Timing for Perioperative Management of Antithrombotic Medications
                     Medication

   Day(s) before                                          Antiplatelets
   or after
   surgery           Direct oral anticoagulants           P2Y12 inhibitors                 Aspirin             Vitamin K antagonists*

   –7 to –10         NA                                   Stop prasugrel (Effient)         Continuing          NA
                                                                                           aspirin through
   –5                NA                                   Stop clopidogrel                 surgery is          Stop vitamin K antagonist
                                                                                           recommended,
   –4                Stop dabigatran (Pradaxa)            Stop ticagrelor (Brilinta;​      otherwise stop      No warfarin
                     if bleeding risk is high and         3 to 5 days)                     at < 7 days prior
                     if glomerular filtration rate
                     < 50 mL per min per 1.73 m2
                     (0.83 mL per s per m2)

   –3                Stop dabigatran if bleeding          Stop ticagrelor;​3 to 5                              Start low-molecular-weight hepa-
                     risk is low or moderate and          days)                                                rin bridging if necessary
                     glomerular filtration rate is                                                             No warfarin
                     < 50 mL per min per 1.73 m2

   –2                Stop direct oral anticoagulant       No prasugrel, clopido-                               Continue low-molecular-weight
                     if high bleeding risk and nor-       grel, ticagrelor                                     heparin
                     mal glomerular filtration rate                                                            No warfarin

   –1                Stop direct oral anticoagulant       No prasugrel, clopido-                               If bridging, give half the daily dosage
                     if low or moderate bleeding          grel, ticagrelor                                     of low-molecular-weight heparin
                     risk and normal glomerular                                                                24 hours before surgery, then stop
                     filtration rate                                                                           low-molecular-weight heparin
                                                                                                               No warfarin

   Surgery           No direct oral anticoagulants        No prasugrel, clopido-                               No low-molecular-weight heparin
                                                          grel, ticagrelor                                     No warfarin

   +1                Restart direct oral antico-          Restart all                                          Restart vitamin K antagonist
                     agulant if low or moderate
                     bleeding risk

   +2                Restart direct oral anticoagu-       NA                                                   Restart low-molecular-weight
                     lant if high bleeding risk                                                                heparin bridging for low- to
                                                                                                               moderate-risk bleeding until inter-
                                                                                                               national normalized ratio at goal

   +3                NA                                   NA                                                   Restart low-molecular-weight
                                                                                                               heparin bridging for high bleeding
                                                                                                               risk until international normalized
                                                                                                               ratio at goal

   NA = not applicable.
   *—If bleeding risk is minimal, warfarin, direct oral anticoagulants, and antiplatelets can be continued.




210 American Family Physician                                  www.aafp.org/afp                                Volume 108, Number 2 ◆ August 2023
                                                  PRACTICE GUIDELINES


glomerular filtration rate is less than 50 mL per min per             P2Y12 platelet receptor inhibitors should be stopped before
1.73 m2, stop dabigatran (Pradaxa) four days before surgery        surgery (Tables 3 and 4). Stop clopidogrel five days before
for high bleeding risk and three days before surgery for low       surgery, ticagrelor (Brilinta) three to five days before surgery,
to moderate bleeding risk.                                         and prasugrel (Effient) seven to 10 days before surgery. All
   Direct oral anticoagulants can be restarted 24 hours            P2Y12 inhibitors can be restarted within 24 hours of surgery
after surgery unless the surgical bleeding risk is high. For a     if hemostasis has been obtained.
surgery with high bleeding risk, delay restarting the medi-           For dual-antiplatelet therapy post stent placement, man-
cation for 48 to 72 hours. Because direct oral anticoagulants      agement depends on the time since stent placement. If the
have a rapid onset, excessive bleeding may occur if they are       patient is within 12 weeks postcoronary stenting, either
started too early. After surgery, the bleeding risk must again     delaying elective surgery or continuing both medications
be balanced against the thrombosis risk. If anticoagulation        is recommended because of the high risk of stent thrombo-
is delayed, low-molecular-weight heparin for venous throm-         sis. For patients who are more than three months after cor-
boembolism prophylaxis after surgery is still recommended.         onary stent placement, the recommendation is to stop the
                                                                   P2Y12 inhibitor and continue aspirin therapy. Bridging these
Management of Vitamin K Antagonist                                 gaps with antiplatelet or anticoagulant medications does not
Medications                                                        improve outcomes.
For patients taking the vitamin K antagonist warfarin, con-
tinue the medication if bleeding risk is minimal. With low          Editor’s Note:​ This is the first update to these guidelines
to moderate or high bleeding risk, stop warfarin;​patients          for management of antithrombotic medications since 2012,
with high thrombosis risk should receive heparin before and         when direct oral anticoagulants were very new. Direct oral
                                                                    anticoagulants are now the recommended anticoagulant
after surgery. In patients who are at low to moderate risk          medication for most patients, and their management is
for thromboembolism, no bridging with heparin is recom-             relatively simple because of their short onset and rapid deg-
mended. For atrial fibrillation, the benefits of bridging are       radation. Because these medications can be held one to
less certain because the stroke risk over a few days is low.        two days before surgery and restarted one to two days after
   Warfarin should be stopped at least five days before the         surgery, bridging with heparin is not recommended, unlike
                                                                    with warfarin. The other interesting recommendation is to
procedure and restarted 12 to 24 hours after the procedure if       continue aspirin through the surgery because of little, if any,
hemostasis has been obtained (Table 4).                             increase in bleeding.—Michael J. Arnold, MD, Assistant Med-
   Heparin bridging can occur with unfractionated heparin           ical Editor
or low-molecular-weight heparin. If intravenous unfraction-
ated heparin is used, heparin should be stopped at least four      Guideline source:​American College of Chest Physicians
hours before the procedure and restarted at least 24 hours         Published source:​ Chest. November 2022;​162(5):​e207-e243.
after the procedure. If low-molecular-weight heparin is used,      Available at:​ https://​journal.chestnet.org/article/
give one-half the daily dosage 24 hours before the proce-          S0012-3692(22)01359-9/fulltext
dure, and wait at least 24 hours after surgery to give the first
postoperative dose of low-molecular-weight heparin. If the         Anne L. du Breuil, MD
                                                                   Thomas Jefferson University
surgery has a high bleeding risk, wait 48 to 72 hours before       Philadelphia, Pa.
restarting heparin to ensure hemostasis.                           Email:​ anne.dubreuil@​jefferson.edu ■


Management of Antiplatelet Medications
Continuing aspirin is recommended for all noncardiac sur-
gery. If stopping aspirin, the American College of Chest Phy-
sicians recommends stopping within seven days of surgery.




August 2023 ◆ Volume 108, Number 2                    www.aafp.org/afp                                 American Family Physician 211
